Meir Rinde

Articles

Survival Gains Prompt Growing Emphasis on Fertility Preservation

May 13th 2019

Improved outcomes such as longer survival have increased interest among patients in pursuing fertility preservation options, and advances in techniques have made it possible for more patients to have children after treatment.

TKI-Immunotherapy Combinations Push the Envelope in Frontline RCC

April 12th 2019

Convincing data have made the case for the use of immunotherapy in the frontline for advanced renal cell carcinoma, ushering in a second revolution in slightly more than a decade.

Experts Say DCIS Requires Focus on Genomics and Microenvironment

March 13th 2019

Identifying patients with ductal carcinoma in situ who are more likely to develop invasive breast cancer remains a challenge, despite decades of research and the development of stratification methods to predict progression and recurrence.

Novel Agents May Change Paradigm for Advanced HER2+ Breast Cancer

March 11th 2019

The treatment of patients with advanced HER2-positive breast cancer could be reshaped in the next several years as clinical trials of several exciting new drugs begin to yield results.

Is the Sipuleucel-T Saga Poised for a New Chapter?

February 6th 2019

Advocates for sipuleucel-T point out that the public has become more aware of and interested in immunotherapy now, and they believe the product has the potential to benefit a larger group of patients.

Robust Future Ahead for Stem Cell Transplants

December 6th 2018

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

The HPV Puzzle: Quest to Deintensify Therapy in Oropharyngeal Cancer Continues

November 6th 2018

After more than 2 decades of change in the epidemiology of oropharyngeal cancers, the choice of optimal treatment for patients with human papillomavirus–positive disease remains elusive.

Genomic Era Reaches Pediatric Oncology

September 4th 2018

Technological advancements in molecular tumor profiling are starting to make a difference in pediatric oncology, where the search for new therapies is challenging and frustrating.

The Comorbidity Checklist: New Strategies Needed for Cancer Care

June 28th 2018

Patients with cancer have high rates of comorbidities, but hard data are often lacking about the interaction of specific regimens with such health conditions. Experts say more inclusive clinical trials and broader use of risk assessment tools would help improve care.

A Whirlwind of Change in Lung Cancer

May 22nd 2018

Novel combination regimens anchored by pembrolizumab (Keytruda), atezolizumab (Tecentriq), or nivolumab (Opdivo) are opening the door to new options and an opportunity to personalize therapy in non–small cell lung cancer.

Debating Value Versus Cost for Immunotherapy

May 16th 2018

In March, the President’s Cancer Panel issued a report acknowledging the financial toxicity associated with cancer care across the spectrum of treatments and suggesting potential remedies.

Patient Shortage for Cancer Trials Grows

April 30th 2018

Amid an explosion of innovation and discovery in the oncology field, researchers are finding it increasingly difficult to recruit enough patients for clinical trials.

NGS Testing Hits Clinical Practice

February 19th 2018

The use of next-generation sequencing to diagnose cancers and guide therapy decisions is expanding as more therapies are linked to genomic abnormalities.

Keeping a Tight Rein on Unnecessary Expenditures in Oncology Practice

January 27th 2018

Doctors from Intermountain Healthcare decided to see if they could improve outcomes of patients placed on expensive machines.

COA Study: Hospital Outpatient Care 60% Higher, Leads to More Emergency Visits

November 23rd 2017

As CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, the results from a new study show that cancer treatment remains much less expensive at community oncology clinics than at hospitals and that the spending gap between the 2 types of sites may be growing wider.

USP Eases the Pressure to Improve Hazardous Drug Management

November 3rd 2017

The hood for handling biologics isn't vented to the outdoors, and there’s no negative-pressure room to safely contain and exhaust potentially tainted air.

CMS Claims Data Provide Glimpse of True Cost Picture

October 27th 2017

As the Oncology Care Model practices work to reduce Medicare’s overall spending on those patients and to earn shared savings payments, the data are providing them with an unprecedented full picture of the extent and cost of care.

Savings Improve Faster Than Care Quality in New Medical Home Pilot

October 12th 2017

Five years ago, Capital BlueCross asked community oncology practices in its network what kind of reimbursement model they would like to try as they worked to stay financially viable and independent.

Time to Focus on Succession Planning as Retirements Loom

July 10th 2017

Joliet Oncology-Hematology decided to create new governance and compensation structures and eventually elected a new president.

Administrators Say OCM Monthly Payments Won't Cover Costs of Improved Care

June 27th 2017

Practices in CMS’ Oncology Care Model are individually receiving hundreds of thousands of dollars in new annual revenue, but physicians and administrators are not exactly celebrating the influx of cash.